FDA Warns Three Baby-Formula Makers Over Violations in Production
By Sabela Ojea
The U.S. Food and Drug Administration issued warning letters to baby-formula manufacturers Reckitt & Benckiser's Mead Johnson Nutrition, Perrigo Wisconsin and ByHeart over their infant formulas.
The U.S. regulator said the three companies violated infant formula regulations, based on data compiled from a number of inspections of their facilities over the past few months.
Each company will have 15 working days to explain what corrective actions they are taking, the FDA said.
The FDA isn't advising parents and caregivers to discard or avoid purchasing any particular infant formula at this time. However, its aim is to make sure infant formula is being produced "under the safest conditions possible."
"The FDA is issuing these letters...to reinforce to these firms the importance of instituting and maintaining appropriate corrective actions when they detect pathogens to ensure compliance with the FDA's laws and regulations," it said.
In December of last year then again in February and March, the FDA initiated formula recalls to remove product potentially contaminated with the bacteria Cronobacter sakazakii.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
August 30, 2023 17:12 ET (21:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations